CRISPR Therapeutics AG (CRSP) Buy, Sell or Hold

CRISPR Therapeutics AG (CRSP)

59.71

-0.37 (0.62%)

as of Jul 2, 2026, 11:32:29 pm Market Open.

39 watching

PARTIAL BUY

He sees this company mentioned in many science papers, but the stock has been a tough own. Overall, he likes it. Buy some now and more if it goes lower. How can this company keep losing money?

COMMENT

Is trading at a fraction of a few years ago. If you know about gene technology, maybe buy this, but doesn't know a lot about this science or business.

BUY

They have some explosive technology. He believes in it.

HOLD

Recent improvements in R&D have been major gain in the business. Is hard to predict future of business given nature of health discoveries. Would recommend holding it.

DON'T BUY

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Biopharmaceutical company building gene editing based medicines for serious diseases. Riskier play, but gene editing would be a massive breakthrough and they have been the leaders in that space for a while. New to the trending stocks with 13 mentions in the past 24 hours.

RISKY

A great spec. It's a genetic engineering company so it's bought on spec, not earnings.

COMMENT

A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)

COMMENT

They produce a gene-editing tool that splices DNA that has the potential of curing diseases such as Huntington's Chorea and cancer. It's new technology, but he can't think of another company doing this. This segment is very rich and a trading opportunity at best.

Showing 1 to 9 of 9 entries

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Hightower

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

CRISPR Therapeutics AG (CRSP) Frequently Asked Questions

What is CRISPR Therapeutics AG stock symbol?

CRISPR Therapeutics AG is a American stock, trading under the symbol CRSP (previously CRSP-Q on Stockchase) on the NASDAQ (CRSP). It is usually referred to as NASDAQ:CRSP or CRSP

Is CRISPR Therapeutics AG a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on CRSP (previously CRSP-Q on Stockchase) on Stockchase. Read the latest expert commentary for CRISPR Therapeutics AG.

Is CRISPR Therapeutics AG a good investment or a top pick?

CRISPR Therapeutics AG was recommended as a Top Pick by Darren Sissons on 2019-04-25. Read the latest stock experts ratings for CRISPR Therapeutics AG.

Why is CRISPR Therapeutics AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for CRISPR Therapeutics AG.

Is CRISPR Therapeutics AG worth watching?

CRISPR Therapeutics AG is followed by 39 investors on Stockchase and is a trending stock that is worth watching.

What is CRISPR Therapeutics AG stock price?

On 2026-07-02, CRISPR Therapeutics AG (CRSP) stock closed at a price of $59.71.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

CRISPR Therapeutics AG (CRSP)